Molecular profile
- Sequence
- YAPLPRWSGPIGVSWGLR
- Molecular Formula
- C 96 H 142 N 26 O 22
- Molecular Weight
- 2012.3492 g/mol
Peptide research profile
PE-22-28
PE-22-28 is a synthetic derivative of the naturally occurring peptide spadin, and it has an affinity for binding to TREK-1, a protein found in brain regions responsible for regulating mood, memory, and learning. Research on PE-22-28 is underway, exploring its potential applications, which include antidepressant effects, enhancement of learning processes, facilitation of stroke recovery, and its role in addressing…
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range200 mcgDosing
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range600 mcgDosing
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
Research on PE-22-28
Understanding TREK-1 and therapeutic applications
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
Research on PE-22-28
Understanding TREK-1 and therapeutic applications
Recorded protocol library
Amounts recorded for PE-22-28
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Dosing · lower endpoint
200 mcg
Sign in for schedule, duration and source context.
- 02
Dosing · upper endpoint
600 mcg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending